These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34946311)

  • 21. Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.
    Canuet L; Pusil S; López ME; Bajo R; Pineda-Pardo JÁ; Cuesta P; Gálvez G; Gaztelu JM; Lourido D; García-Ribas G; Maestú F
    J Neurosci; 2015 Jul; 35(28):10325-30. PubMed ID: 26180207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of subjective sleep characteristics and plasma biomarkers of Alzheimer's disease pathology in older cognitively unimpaired adults with higher amyloid-β burden.
    Chu H; Huang C; Miao Y; Ren C; Guan Y; Xie F; Fang Z; Guo Q
    J Neurol; 2023 Jun; 270(6):3008-3021. PubMed ID: 36806992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
    Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
    Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
    He B; Wang L; Xu B; Zhang Y;
    Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.
    Hosseini AA; Brown T; Mannino L; Gran B; Junaid K; Mukaetova-Ladinska EB
    J Alzheimers Dis; 2022; 87(2):771-780. PubMed ID: 35404281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute sleep loss decreases CSF-to-blood clearance of Alzheimer's disease biomarkers.
    Liu H; Barthélemy NR; Ovod V; Bollinger JG; He Y; Chahin SL; Androff B; Bateman RJ; Lucey BP
    Alzheimers Dement; 2023 Jul; 19(7):3055-3064. PubMed ID: 36695437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias.
    Haroon J; Jordan K; Mahdavi K; Rindner E; Becerra S; Surya JR; Zielinski M; Venkatraman V; Goodenowe D; Hofmeister K; Zhang J; Ahlem C; Reading C; Palumbo J; Pourat B; Kuhn T; Jordan S
    Medicine (Baltimore); 2024 Jul; 103(30):e39027. PubMed ID: 39058809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease.
    García-Escobar G; Puig-Pijoan A; Puente-Periz V; Fernández-Lebrero A; María Manero R; Navalpotro-Gómez I; Suárez-Calvet M; Grau-Rivera O; Contador-Muñana J; Cascales-Lahoz D; Duran-Jordà X; Boltes N; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas MD; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Padrós-Fluvià A; Peña-Casanova J; Sánchez-Benavides G
    J Alzheimers Dis; 2023; 92(4):1303-1321. PubMed ID: 37038810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO.
    Ismail Z; Leon R; Creese B; Ballard C; Robert P; Smith EE
    Mol Neurodegener; 2023 Jul; 18(1):50. PubMed ID: 37516848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.
    Okonkwo OC; Mielke MM; Griffith HR; Moghekar AR; O'Brien RJ; Shaw LM; Trojanowski JQ; Albert MS;
    Arch Neurol; 2011 Jan; 68(1):113-9. PubMed ID: 21220682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep Characteristics and Cognitive Function in Older Adults Without Dementia: The CABLE Study.
    Fu Y; Wang ZT; Qu Y; Wang XT; Ma YH; Bi YL; Dong Q; Tan L; Yu JT
    J Alzheimers Dis; 2021; 84(3):1029-1038. PubMed ID: 34602483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations.
    Sturchio A; Dwivedi AK; Malm T; Wood MJA; Cilia R; Sharma JS; Hill EJ; Schneider LS; Graff-Radford NR; Mori H; Nübling G; El Andaloussi S; Svenningsson P; Ezzat K; Espay AJ;
    J Alzheimers Dis; 2022; 90(1):333-348. PubMed ID: 36120786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.